To include your compound in the COVID-19 Resource Center, submit it here.

Blame the inhibitor, not the target

While matrix metalloprotease (MMP) inhibitors have been unsuccessful in the clinic so far, new understanding of the biology of MMPs and the chemistry of their inhibitors suggests that difficulties in developing these products may be due to the characteristics of the inhibitors.

Matthew Laufersweller of Procter & Gamble

Read the full 479 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers